Flutafuranol F 18

Drug Profile

Flutafuranol F 18

Alternative Names: [18F]-AZD4694; [18F]-NAV4694; AZD-4694; NAV-4694

Latest Information Update: 11 Aug 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Benzofurans; Fluorinated hydrocarbons; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 08 Aug 2016 Navidea Biopharmaceuticals enters a term sheet agreement for sub-licensing Flutafuranol F 18 to Cerveau Technologies
  • 12 Feb 2016 Phase-III development is ongoing in USA (NCT01886820)
  • 05 Mar 2015 Flutafuranol F 18 is available for licensing as of 05 Mar 2015. www.neoprobe.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top